Abbott Laboratories
Abbott Expands Colorectal Cancer Screening Options With New Blood Test
·Consolidated from 1 source
Abbott Laboratories has introduced a new blood test for colorectal cancer screening, expanding its portfolio in this area. The launch of SimpleScreen™ CRC aims to provide additional options for patients and healthcare providers. This new test complements the company's existing offerings in cancer diagnostics.
Abbott Laboratories has announced the launch of its new SimpleScreen™ CRC blood test, broadening its range of diagnostic tools for colorectal cancer. This development marks a significant addition to the company's growing suite of cancer screening solutions.
The introduction of SimpleScreen™ CRC is intended to offer more choices for individuals and their physicians in the ongoing effort to detect colorectal cancer. The test is designed to work alongside other screening methods, emphasizing Abbott's commitment to advancing cancer diagnostics.
Coverage today notes that the new test complements Abbott's existing colorectal cancer screening portfolio, which includes products like Cologuard Plus®. This expansion reflects the company's strategy to provide comprehensive solutions for patient health management and early disease detection. The focus remains on making screening more accessible and effective for a wider population.
Sources
This recap was generated by consolidating the public headlines below.